Original Title: 자료연계 가능성 검토를 위한 의료기술 평가 연구

Authors' recommendations: This study linked data from various sources. However, there were difficulties owing to the stringent laws on the use of personal information. Therefore, it may be helpful to establish a legal basis to waive the informed consent process for individual subjects when conducting research for public benefit. Regarding the cardiovascular disease occurrence in type 2 diabetes patients treated with oral hypoglycemic agents, metformin use significantly reduced cardiovascular risk. In addition, in the context of secondary drugs, the TZD and DPP4 groups had significantly lower risks than the sulfonylurea group. The results of the present study form a foundation for a future large-scale randomized controlled clinical trial. Liver, pancreatic, colon, and rectal cancer patients with diabetes and on metformin (with high medication adherence) who underwent curative resection exhibited a lower all-cause mortality rate than other groups. In liver, colon, and rectal cancer, the relapse rates were lower with metformin use. These findings based on public data in Korea provide valuable epidemiological evidence of the anti-cancer effect of metformin, specifically by reducing mortality and relapse rates.

Project Status: Completed

Year Published: 2016

URL for published report: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=181

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: South Korea

Organisation Name: National Evidence-based healthcare Collaborating Agency

Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.

Contact Name: int@neca.re.kr

Contact Email: int@neca.re.kr

Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)